FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996392810> ?p ?o ?g. }

• W2996392810 endingPage "1086" @default.
• W2996392810 startingPage "1065" @default.
• W2996392810 abstract "Teneligliptin is a dipeptidyl peptidase 4 inhibitor that was approved for the treatment of type 2 diabetes mellitus (T2DM) in Japan in 2012. We performed a long-term post-marketing surveillance (RUBY) to obtain real-world evidence regarding the safety and efficacy of teneligliptin in Japan. This 3-year follow-up RUBY surveillance registered patients with T2DM who started treatment with teneligliptin between May 2013 and February 2015 in Japan. Collected data included demographics, treatments, adverse drug reactions (ADRs) and laboratory variables. Data were evaluated in all patients and in patients divided according to baseline renal function across categories of estimated glomerular filtration rate (G1–G5) and dialysis. Safety was assessed as the incidence of ADRs and efficacy was assessed in terms of glycaemic control, for up to 3 years. Of 11,677 patients registered, 10,696 and 10,249 were evaluable for safety and efficacy analyses, respectively. The median duration of exposure was 1096 days. ADRs occurred in 412 patients (3.85%) and were serious in 117 patients (1.09%). The most frequent ADR class was gastrointestinal disorders (0.68%), which included constipation. There were no new ADRs warranting attention beyond those already described in teneligliptin’s package insert. ADRs and serious ADRs in renal function subgroups occurred in 3.24–7.14% and 0.65–5.36% in G1–G5, and 4.49% and 1.92% in patients on dialysis, respectively. Reduction in HbA1c was sustained for 3 years after starting teneligliptin (− 0.70% ± 1.36%, p < 0.001 at 3 years). The least-squares mean changes in HbA1c adjusted for baseline were − 0.76% to − 0.66% in G1–G5 at 3 years. Glycated albumin levels decreased in patients on dialysis (− 2.92% ± 4.78% at 3 years). There were no new safety or efficacy concerns about teneligliptin used in long-term, real-world, clinical settings in patients with T2DM with any stages of renal impairment. Japan Pharmaceutical Information Center clinical trials database identifier: Japic CTI-153047. Plain language summary available for this article." @default.
• W2996392810 created "2019-12-26" @default.
• W2996392810 creator A5012305266 @default.
• W2996392810 creator A5027143314 @default.
• W2996392810 creator A5040548657 @default.
• W2996392810 creator A5044544721 @default.
• W2996392810 creator A5058512882 @default.
• W2996392810 creator A5085600285 @default.
• W2996392810 date "2019-12-23" @default.
• W2996392810 modified "2023-10-16" @default.
• W2996392810 title "Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan" @default.
• W2996392810 cites W1494558589 @default.
• W2996392810 cites W1944521216 @default.
• W2996392810 cites W1982796090 @default.
• W2996392810 cites W1996141009 @default.
• W2996392810 cites W1996638018 @default.
• W2996392810 cites W1998401806 @default.
• W2996392810 cites W2015017251 @default.
• W2996392810 cites W2026669955 @default.
• W2996392810 cites W2041642658 @default.
• W2996392810 cites W2056182647 @default.
• W2996392810 cites W2083783651 @default.
• W2996392810 cites W2083861834 @default.
• W2996392810 cites W2092721777 @default.
• W2996392810 cites W2120655733 @default.
• W2996392810 cites W2133731486 @default.
• W2996392810 cites W2137998134 @default.
• W2996392810 cites W2139923324 @default.
• W2996392810 cites W2150293876 @default.
• W2996392810 cites W2152189242 @default.
• W2996392810 cites W2338042410 @default.
• W2996392810 cites W2494769690 @default.
• W2996392810 cites W2521756482 @default.
• W2996392810 cites W2560350129 @default.
• W2996392810 cites W2564952768 @default.
• W2996392810 cites W2737924655 @default.
• W2996392810 cites W2744768807 @default.
• W2996392810 cites W2767087620 @default.
• W2996392810 cites W2772190174 @default.
• W2996392810 cites W2780972107 @default.
• W2996392810 cites W2790289355 @default.
• W2996392810 cites W2791950638 @default.
• W2996392810 cites W2792715720 @default.
• W2996392810 cites W2797990830 @default.
• W2996392810 cites W2804073089 @default.
• W2996392810 cites W2809062680 @default.
• W2996392810 cites W2888756239 @default.
• W2996392810 cites W2895533920 @default.
• W2996392810 cites W2897178174 @default.
• W2996392810 cites W2898451146 @default.
• W2996392810 cites W2906004003 @default.
• W2996392810 cites W2906184191 @default.
• W2996392810 cites W2922062263 @default.
• W2996392810 cites W2937146242 @default.
• W2996392810 cites W2940985503 @default.
• W2996392810 cites W2964990826 @default.
• W2996392810 cites W4211003831 @default.
• W2996392810 cites W4211025575 @default.
• W2996392810 cites W4250208868 @default.
• W2996392810 cites W817755157 @default.
• W2996392810 doi "https://doi.org/10.1007/s12325-019-01189-w" @default.
• W2996392810 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7089720" @default.
• W2996392810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31873865" @default.
• W2996392810 hasPublicationYear "2019" @default.
• W2996392810 type Work @default.
• W2996392810 sameAs 2996392810 @default.
• W2996392810 citedByCount "15" @default.
• W2996392810 countsByYear W29963928102020 @default.
• W2996392810 countsByYear W29963928102021 @default.
• W2996392810 countsByYear W29963928102022 @default.
• W2996392810 countsByYear W29963928102023 @default.
• W2996392810 crossrefType "journal-article" @default.
• W2996392810 hasAuthorship W2996392810A5012305266 @default.
• W2996392810 hasAuthorship W2996392810A5027143314 @default.
• W2996392810 hasAuthorship W2996392810A5040548657 @default.
• W2996392810 hasAuthorship W2996392810A5044544721 @default.
• W2996392810 hasAuthorship W2996392810A5058512882 @default.
• W2996392810 hasAuthorship W2996392810A5085600285 @default.
• W2996392810 hasBestOaLocation W29963928101 @default.
• W2996392810 hasConcept C121332964 @default.
• W2996392810 hasConcept C126322002 @default.
• W2996392810 hasConcept C134018914 @default.
• W2996392810 hasConcept C177713679 @default.
• W2996392810 hasConcept C197636746 @default.
• W2996392810 hasConcept C197934379 @default.
• W2996392810 hasConcept C198451711 @default.
• W2996392810 hasConcept C2777180221 @default.
• W2996392810 hasConcept C555293320 @default.
• W2996392810 hasConcept C61797465 @default.
• W2996392810 hasConcept C62520636 @default.
• W2996392810 hasConcept C71924100 @default.
• W2996392810 hasConcept C99454951 @default.
• W2996392810 hasConceptScore W2996392810C121332964 @default.
• W2996392810 hasConceptScore W2996392810C126322002 @default.
• W2996392810 hasConceptScore W2996392810C134018914 @default.
• W2996392810 hasConceptScore W2996392810C177713679 @default.
• W2996392810 hasConceptScore W2996392810C197636746 @default.
• W2996392810 hasConceptScore W2996392810C197934379 @default.

• next